Genflow Biosciences Ltd saw its stock climb 13% following the announcement of a new independent non-executive chairman. Investors interpreted the move as a clear signal that the company is shifting from early-stage research toward a stronger focus on commercial execution. Trading volumes on the London Stock Exchange increased by 40% compared with the daily average, underscoring heightened market interest in the group’s progress as its gene therapy pipeline reaches key development milestones.

Gad Berdugo joined the board with immediate effect, bringing over 25 years of experience in life-science leadership and commercialisation. Berdugo previously held senior roles at a leading cell therapy firm where he oversaw three successful product launches generating combined annual revenues in excess of £200 million. His appointment complements Tamara Joseph’s continued role as a director, ensuring continuity in board oversight while adding deeper expertise in advancing gene therapy assets toward clinical trials and eventual market approval.